<!DOCTYPE html>
<html lang="zh-TW">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Finerenone 台灣真實世界臨床分析</title>
    <style>
        @import url('https://fonts.googleapis.com/css2?family=Noto+Sans+TC:wght@300;400;500;700&display=swap');

        :root {
            --bg-color: #F9F6F0; /* 溫暖米白 */
            --text-color: #4A4036; /* 深灰棕 */
            --primary-color: #D4A373; /* 赤陶/駝色 */
            --secondary-color: #8A9A5B; /* 鼠尾草綠 */
            --accent-color: #E9C46A; /* 柔和琥珀 */
            --card-bg: #FFFFFF;
            --border-color: #E0D8C3;
        }

        body {
            background-color: var(--bg-color);
            color: var(--text-color);
            font-family: 'Noto Sans TC', sans-serif;
            margin: 0;
            padding: 0;
            line-height: 1.7;
            background-image: radial-gradient(#E0D8C3 1px, transparent 1px);
            background-size: 30px 30px;
        }

        header {
            background-color: var(--card-bg);
            padding: 50px 20px;
            text-align: center;
            border-bottom: 4px solid var(--primary-color);
            box-shadow: 0 4px 15px rgba(0,0,0,0.05);
        }

        h1 {
            color: var(--primary-color);
            font-size: 2.2em;
            margin: 0;
            font-weight: 700;
            letter-spacing: 1px;
        }

        .subtitle {
            color: var(--secondary-color);
            font-size: 1.2em;
            margin-top: 10px;
            font-weight: 500;
        }

        .container {
            max-width: 1000px;
            margin: 40px auto;
            padding: 0 20px;
        }

        /* 導覽列 (Tabs) */
        .tab-menu {
            display: flex;
            justify-content: center;
            flex-wrap: wrap;
            gap: 10px;
            margin-bottom: 30px;
        }

        .tab-btn {
            background-color: var(--card-bg);
            color: var(--text-color);
            border: 2px solid var(--border-color);
            padding: 12px 24px;
            border-radius: 30px;
            cursor: pointer;
            font-size: 1em;
            font-weight: 500;
            transition: all 0.3s ease;
            box-shadow: 0 2px 5px rgba(0,0,0,0.02);
            font-family: 'Noto Sans TC', sans-serif;
        }

        .tab-btn:hover {
            border-color: var(--primary-color);
            transform: translateY(-2px);
        }

        .tab-btn.active {
            background-color: var(--primary-color);
            color: white;
            border-color: var(--primary-color);
            box-shadow: 0 4px 10px rgba(212, 163, 115, 0.3);
        }

        /* 內容區塊 */
        .content-section {
            display: none;
            background-color: var(--card-bg);
            border-radius: 15px;
            padding: 40px;
            box-shadow: 0 10px 30px rgba(74, 64, 54, 0.08);
            border: 1px solid var(--border-color);
            animation: fadeIn 0.4s ease-in-out;
        }

        .content-section.active {
            display: block;
        }

        h2 {
            color: var(--secondary-color);
            border-bottom: 2px solid var(--accent-color);
            padding-bottom: 10px;
            margin-top: 0;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .icon {
            width: 1.1em;
            height: 1.1em;
            stroke: currentColor;
            fill: none;
            stroke-width: 1.8;
            stroke-linecap: round;
            stroke-linejoin: round;
            flex-shrink: 0;
            vertical-align: -0.15em;
        }

        .with-icon {
            display: inline-flex;
            align-items: center;
            gap: 8px;
        }

        .icon-emphasis {
            color: var(--primary-color);
        }

        /* 數據卡片 (Grid) */
        .data-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
            gap: 20px;
            margin-top: 20px;
        }

        .data-card {
            background-color: var(--bg-color);
            padding: 20px;
            border-radius: 10px;
            text-align: center;
            border: 1px solid var(--border-color);
            transition: transform 0.3s;
        }

        .data-card:hover {
            transform: translateY(-5px);
        }

        .data-value {
            font-size: 2em;
            font-weight: 700;
            color: var(--primary-color);
            margin: 10px 0;
        }

        .data-label {
            font-size: 0.9em;
            color: var(--text-color);
            font-weight: 500;
        }

        /* 表格設計 */
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            background-color: white;
        }

        th, td {
            padding: 15px;
            text-align: left;
            border-bottom: 1px solid var(--border-color);
        }

        th {
            background-color: var(--bg-color);
            color: var(--secondary-color);
            font-weight: 600;
        }

        tr:hover {
            background-color: #FDFBF7;
        }

        .highlight {
            color: var(--primary-color);
            font-weight: 700;
        }

        .good-news {
            color: var(--secondary-color);
            font-weight: 700;
        }

        @keyframes fadeIn {
            from { opacity: 0; transform: translateY(10px); }
            to { opacity: 1; transform: translateY(0); }
        }

        /* UACR Chart */
        .chart-bar-container {
            margin: 20px 0;
        }
        .chart-row {
            display: flex;
            align-items: center;
            margin-bottom: 15px;
        }
        .chart-label {
            width: 100px;
            font-weight: 500;
        }
        .chart-bar-bg {
            flex-grow: 1;
            background-color: #EFEFEF;
            border-radius: 20px;
            height: 24px;
            overflow: hidden;
            position: relative;
        }
        .chart-bar-fill {
            height: 100%;
            background-color: var(--secondary-color);
            border-radius: 20px;
            display: flex;
            align-items: center;
            padding-left: 10px;
            color: white;
            font-size: 0.85em;
            transition: width 1.5s ease;
        }
        .chart-bar-fill.start { background-color: var(--primary-color); }
    </style>
</head>
<body>

    <header>
        <h1><span class="with-icon"><svg class="icon" viewBox="0 0 24 24" aria-hidden="true"><path d="M12 21c0-6.5 3.5-11 9-13-1 6.5-4.5 11-9 13Z"></path><path d="M12 21C5.5 18.5 3 13 3 6c5 1.2 8 4.5 9 9"></path></svg>Real-World Experience of Finerenone</span></h1>
        <div class="subtitle">奇美醫療體系多中心回溯性世代研究 (N = 166)</div>
        <p style="color: #888; font-size: 0.9em; margin-top: 15px;">Data Source: Chi Mei Medical Center (Aug 2023 - Oct 2024)</p>
    </header>

    <div class="container">
        <div class="tab-menu">
            <button class="tab-btn active" onclick="openTab('study-design')"><span class="with-icon"><svg class="icon" viewBox="0 0 24 24" aria-hidden="true"><path d="M4 4h11a3 3 0 0 1 3 3v13H7a3 3 0 0 0-3 3V4Z"></path><path d="M7 20h13V7a3 3 0 0 0-3-3"></path><path d="M8.5 9.5h6"></path><path d="M8.5 13h6"></path></svg>研究設計</span></button>
            <button class="tab-btn" onclick="openTab('table1')"><span class="with-icon"><svg class="icon" viewBox="0 0 24 24" aria-hidden="true"><circle cx="9" cy="8" r="3"></circle><circle cx="17" cy="9" r="2.5"></circle><path d="M3.5 19.5a5.5 5.5 0 0 1 11 0"></path><path d="M13.5 19.5a4.5 4.5 0 0 1 7 0"></path></svg>基礎特徵 (Table 1)</span></button>
            <button class="tab-btn" onclick="openTab('table2')"><span class="with-icon"><svg class="icon" viewBox="0 0 24 24" aria-hidden="true"><path d="M12 3s6 6 6 10a6 6 0 1 1-12 0c0-4 6-10 6-10Z"></path><path d="M9.5 13.5a2.5 2.5 0 0 0 5 0"></path></svg>腎臟結果 (Table 2)</span></button>
            <button class="tab-btn" onclick="openTab('table3')"><span class="with-icon"><svg class="icon" viewBox="0 0 24 24" aria-hidden="true"><path d="M12 21s-7-4.5-7-10a4 4 0 0 1 7-2.5A4 4 0 0 1 19 11c0 5.5-7 10-7 10Z"></path></svg>臨床與安全性 (Table 3)</span></button>
            <button class="tab-btn" onclick="openTab('subgroup')"><span class="with-icon"><svg class="icon" viewBox="0 0 24 24" aria-hidden="true"><circle cx="11" cy="11" r="6"></circle><path d="m20 20-3.5-3.5"></path><path d="M11 8v6"></path><path d="M8 11h6"></path></svg>次族群分析</span></button>
        </div>

        <div id="study-design" class="content-section active">
            <h2><svg class="icon" viewBox="0 0 24 24" aria-hidden="true"><path d="M8 3h8"></path><rect x="5" y="4" width="14" height="17" rx="2"></rect><path d="M8.5 9h7"></path><path d="M8.5 13h7"></path><path d="M8.5 17h4"></path></svg>研究設計與族群 (Study Design & Population)</h2>
            <p>本研究為南台灣首份針對 <strong>Finerenone (nsMRA)</strong> 的多中心真實世界數據 (RWD)。旨在評估其於慢性腎臟病 (CKD) 患者中之療效與安全性。</p>
            
            <div class="data-grid">
                <div class="data-card">
                    <div class="data-value">166</div>
                    <div class="data-label">總收案人數 (N)</div>
                </div>
                <div class="data-card">
                    <div class="data-value">276 天</div>
                    <div class="data-label">平均追蹤時間</div>
                </div>
                <div class="data-card">
                    <div class="data-value">15.7%</div>
                    <div class="data-label">非糖尿病 CKD 比例</div>
                </div>
            </div>
            
            <p style="margin-top: 20px; border-left: 4px solid var(--primary-color); padding-left: 15px;">
                <strong>核心看點：</strong>本族群相較於大型 RCT (如 FIDELIO-DKD) 涵蓋了更廣泛的真實世界患者，包含早期與晚期 CKD，以及高比例同時使用 SGLT2i (72.9%) 的患者。
            </p>
        </div>

        <div id="table1" class="content-section">
            <h2><svg class="icon" viewBox="0 0 24 24" aria-hidden="true"><circle cx="9" cy="8" r="3"></circle><circle cx="17" cy="9" r="2.5"></circle><path d="M3.5 19.5a5.5 5.5 0 0 1 11 0"></path><path d="M13.5 19.5a4.5 4.5 0 0 1 7 0"></path></svg>基準特徵 (Baseline Characteristics)</h2>
            <p>收案患者的平均年齡為 66.5 歲，具有高度的共病比例與當代標準治療 (Guideline-directed medical therapy) 的覆蓋率。</p>
            <table>
                <tr>
                    <th>變數 (Variables)</th>
                    <th>整體數值 (Total N=166)</th>
                </tr>
                <tr>
                    <td>平均年齡 (Age)</td>
                    <td>66.5 ± 11.3 歲</td>
                </tr>
                <tr>
                    <td>男性比例 (Male)</td>
                    <td>77.1%</td>
                </tr>
                <tr>
                    <td>糖尿病 (Diabetes Mellitus)</td>
                    <td>84.3%</td>
                </tr>
                <tr>
                    <td>平均 eGFR</td>
                    <td>43.5 ± 24.9 mL/min/1.73m²</td>
                </tr>
                <tr>
                    <td>中位數 UACR</td>
                    <td>610.5 mg/g</td>
                </tr>
                <tr>
                    <td>共用藥物：RAS Blockers</td>
                    <td>86.1%</td>
                </tr>
                <tr>
                    <td>共用藥物：<span class="highlight">SGLT2 inhibitors</span></td>
                    <td><span class="highlight">72.9%</span></td>
                </tr>
            </table>
        </div>

        <div id="table2" class="content-section">
            <h2><svg class="icon" viewBox="0 0 24 24" aria-hidden="true"><path d="M12 3s6 6 6 10a6 6 0 1 1-12 0c0-4 6-10 6-10Z"></path><path d="M9.5 13.5a2.5 2.5 0 0 0 5 0"></path></svg>腎臟結果 (Renal Outcomes)</h2>
            
            <h3>1. eGFR 軌跡 (穩定維持)</h3>
            <p>治療期間，患者的腎絲球過濾率 (eGFR) 於 Day 30, Day 90, Day 180 均未出現顯著下降 (均 P > 0.4)。證明在真實世界中，Finerenone 展現了高度的腎功能穩定性。</p>

            <h3 style="margin-top: 30px;">2. 蛋白尿顯著改善 (UACR Reduction)</h3>
            <p>與基準值相比，在治療第 180 天時，尿液白蛋白 (UACR) 達到了 <span class="good-news">極具統計學意義的下降 (P=0.001)</span>。</p>
            
            <div class="chart-bar-container">
                <div class="chart-row">
                    <div class="chart-label">Baseline</div>
                    <div class="chart-bar-bg">
                        <div class="chart-bar-fill start" style="width: 100%;">610.5 mg/g (基準值)</div>
                    </div>
                </div>
                <div class="chart-row">
                    <div class="chart-label">Day 180</div>
                    <div class="chart-bar-bg">
                        <div class="chart-bar-fill" style="width: 54%;">332.1 mg/g (下降 ~46%)</div>
                    </div>
                </div>
            </div>
            <p style="font-size: 0.9em; color: #666;">*備註：此 ~46% 的降幅甚至超越了全球樞紐試驗 FIDELIO-DKD (~31%) 的結果。</p>
        </div>

        <div id="table3" class="content-section">
            <h2><svg class="icon" viewBox="0 0 24 24" aria-hidden="true"><path d="M12 21s-7-4.5-7-10a4 4 0 0 1 7-2.5A4 4 0 0 1 19 11c0 5.5-7 10-7 10Z"></path></svg>臨床事件與安全性 (Clinical & Safety Outcomes)</h2>
            
            <div style="display: flex; flex-wrap: wrap; gap: 20px;">
                <div style="flex: 1; min-width: 300px;">
                    <h3 style="color: var(--primary-color);"><span class="with-icon"><svg class="icon" viewBox="0 0 24 24" aria-hidden="true"><circle cx="12" cy="12" r="8"></circle><circle cx="12" cy="12" r="4"></circle><circle cx="12" cy="12" r="1"></circle></svg>療效指標 (Efficacy)</span></h3>
                    <table>
                        <tr>
                            <th>事件</th>
                            <th>發生率 (%)</th>
                        </tr>
                        <tr>
                            <td>全死因死亡 (All-cause mortality)</td>
                            <td>1.2% (2人)</td>
                        </tr>
                        <tr>
                            <td>非致命性心梗 (Nonfatal MI)</td>
                            <td>1.2% (2人)</td>
                        </tr>
                        <tr>
                            <td>血清肌酸酐翻倍 (Cr Doubling)</td>
                            <td><span class="good-news">1.2% (僅2人)</span></td>
                        </tr>
                    </table>
                </div>

                <div style="flex: 1; min-width: 300px;">
                    <h3 style="color: var(--primary-color);"><span class="with-icon"><svg class="icon" viewBox="0 0 24 24" aria-hidden="true"><path d="M12 3 5 6v5c0 5 3.5 8 7 10 3.5-2 7-5 7-10V6l-7-3Z"></path><path d="m9.5 12 2 2 3-3"></path></svg>安全性指標 (Safety)</span></h3>
                    <table>
                        <tr>
                            <th>事件</th>
                            <th>發生率 (%)</th>
                        </tr>
                        <tr>
                            <td>急性腎損傷 (AKI)</td>
                            <td>1.2%</td>
                        </tr>
                        <tr>
                            <td>整體高血鉀 (K > 5 mEq/L)</td>
                            <td>19.3%</td>
                        </tr>
                        <tr>
                            <td>- 輕度 (Mild, K 5-6 mEq/L)</td>
                            <td>18.7%</td>
                        </tr>
                        <tr>
                            <td>- <span class="highlight">重度 (Severe, K > 6 mEq/L)</span></td>
                            <td><span class="highlight">1.8%</span></td>
                        </tr>
                    </table>
                </div>
            </div>
            <p style="margin-top: 15px; background: #FDFBF7; padding: 10px; border-radius: 5px;">
                <span class="with-icon icon-emphasis"><svg class="icon" viewBox="0 0 24 24" aria-hidden="true"><path d="M12 3v12"></path><path d="M9 12h6"></path><path d="M8 17h8"></path><path d="M9 21h6"></path><path d="M7 8a5 5 0 1 1 10 0"></path></svg></span><strong>臨床觀點：</strong> 雖然整體高血鉀發生率約 19.3%，但高達 <strong>96.7%</strong> 的高血鉀事件屬於輕度，嚴重高血鉀 (1.8%) 發生率極低，且與國際 FIDELITY 試驗 (1.1%) 結果高度吻合，顯示安全性極高。
            </p>
        </div>

        <div id="subgroup" class="content-section">
            <h2><svg class="icon" viewBox="0 0 24 24" aria-hidden="true"><circle cx="11" cy="11" r="6"></circle><path d="m20 20-3.5-3.5"></path><path d="M11 8v6"></path><path d="M8 11h6"></path></svg>次族群與敏感度分析 (Subgroup Analysis)</h2>
            <p>我們針對「高血鉀發生率」進行了潛在因子的交叉比對：</p>

            <div class="data-grid">
                <div class="data-card">
                    <div class="data-label">合併使用 SGLT2i</div>
                    <div class="data-value" style="color: var(--secondary-color);">17.4%</div>
                    <div class="data-label">高血鉀發生率</div>
                </div>
                <div class="data-card">
                    <div class="data-label">無使用 SGLT2i</div>
                    <div class="data-value" style="color: #c0392b;">24.4%</div>
                    <div class="data-label">高血鉀發生率</div>
                </div>
            </div>

            <p style="margin-top: 20px; line-height: 1.8;">
                <span class="with-icon icon-emphasis"><svg class="icon" viewBox="0 0 24 24" aria-hidden="true"><path d="M12 2v4"></path><path d="M12 18v4"></path><path d="M4.9 4.9l2.8 2.8"></path><path d="M16.3 16.3l2.8 2.8"></path><path d="M2 12h4"></path><path d="M18 12h4"></path><path d="M4.9 19.1 7.7 16.3"></path><path d="m16.3 7.7 2.8-2.8"></path><circle cx="12" cy="12" r="3.5"></circle></svg></span><strong>黃金搭檔效應 (SGLT2i Co-therapy)：</strong><br>
                數據清楚顯示，<strong>合併使用 SGLT2i 的患者，其高血鉀風險實質上低於未使用者 (17.4% vs 24.4%)</strong>。這證實了 SGLT2i 可能透過促進尿鈉與尿鉀排泄的機制，完美抵銷了 Finerenone 潛在的高血鉀副作用。<br><br>
                此外，起始劑量 (10mg vs 20mg) 與早/晚期 CKD 分期，皆不影響藥物的整體安全防護效果。
            </p>
        </div>
    </div>

    <script>
        function openTab(tabId) {
            // 隱藏所有內容
            let sections = document.getElementsByClassName("content-section");
            for (let i = 0; i < sections.length; i++) {
                sections[i].classList.remove("active");
            }
            
            // 移除所有按鈕的 active 狀態
            let tabs = document.getElementsByClassName("tab-btn");
            for (let i = 0; i < tabs.length; i++) {
                tabs[i].classList.remove("active");
            }
            
            // 顯示當前選中的內容與按鈕狀態
            document.getElementById(tabId).classList.add("active");
            event.currentTarget.classList.add("active");
        }
    </script>
</body>
</html>
